Bruce K Patterson

USPTO Granted Patents = 25 (Patent Applications = 13)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 12)

Average Co-Inventor Count = 1.6

ph-index = 7

Forward Citations = 152(Granted Patents)

Location History:

Chicago, IL (US) (1998 - 2005)
Palo Alto, CA (US) (2009 - 2023)
Menlo Park, CA (US) (2021 - 2024)

Company Filing History:

Northwestern University

4. 7 out of 832,843

Other

patents

Years Active: 1998-2025

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12298309 - Methods of assaying neoplastic and neoplasia-related cells and uses thereof (2025-05-13),

2. 12228580 - Methods of assigning a COVID pathological type based on a cytokine/chemokine panel (2025-02-18),

3. 11952373 - Method of treating hypercytokinemia by administering the CCR5/CCL5 (RANTES) interaction inhibitor maraviroc (2024-04-09),

4. 11726089 - Methods of assaying neoplastic and neoplasia-related cells and uses thereof (2023-08-15),

5. 11629196 - Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions (2023-04-18),

6. 11402391 - Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist (2022-08-02),

7. 11180491 - Method of treating COVID-19 by administering the CCR5/CCL5 (RANTES) interaction inhibitor maraviroc (2021-11-23),

8. 11045546 - Methods of treating coronavirus infection (2021-06-29),

9. 10782298 - Methods of detecting per cell PD-L1 expression and uses thereof (2020-09-22),

10. 10308990 - Methods of evaluating a cellular sample for latent cellular replication competent HIV-1 (2019-06-04),

11. 10167526 - Methods and systems for predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion from a suspension sample of cervical cells (2019-01-01),

12. 10011884 - Methods and systems for predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion from a suspension sample of cervical cells (2018-07-03),

13. 9464332 - HPV E6, E7 MRNA assay and methods of use thereof (2016-10-11),

14. 8653250 - HPV E6, E7 MRNA assay and methods of use thereof (2014-02-18),

15. 7888032 - HPV E6, E7 mRNA assay and methods of use thereof (2011-02-15),

Title: Bruce K Patterson - Innovator in COVID-19 Therapeutics

Introduction

Bruce K Patterson is a prominent inventor located in Palo Alto, California, renowned for his contributions to the field of medical innovation, particularly in the context of COVID-19. With a remarkable portfolio of 24 patents, Patterson has made significant strides in understanding and treating the complexities associated with the virus.

Latest Patents

Among his latest inventions, Patterson has developed methods for assigning a COVID pathological type based on a cytokine/chemokine panel. These innovative methods enable healthcare professionals to determine a COVID pathological type for individuals suffering from COVID-19 by analyzing a quantitative, multiplex cytokine/chemokine panel from a test sample. Furthermore, he has introduced methods aimed at treating individuals, especially long haulers, suffering from chronic COVID-19. His approach involves the administration of a CCR5/CCL5 interaction inhibitor to facilitate recovery and has broad applications in patient stratification, treatment determination, and therapy response assessment.

Additionally, Patterson has designed methods for treating hypercytokinemia related to COVID-19. These methods focus on administering an effective amount of a CCR5 antagonist, such as maraviroc, to address symptoms associated with the disease. He also provides techniques for assessing disease severity through the measurement of CCL5/RANTES levels in patients.

Career Highlights

Bruce K Patterson has worked extensively in the research and development environment, particularly with a focus on pharmaceutical innovations. He has been affiliated with Incelldx, Inc., where his work has contributed to advancements in COVID-19 treatment methodologies. His comprehensive background in medical research underscores his commitment to addressing critical health challenges.

Collaborations

Throughout his career, Patterson has collaborated with notable colleagues including Edgar B Francisco and Amruta Pise. These partnerships reflect a collaborative spirit that fosters innovation in developing effective medical solutions.

Conclusion

Bruce K Patterson stands as a key figure in the ongoing battle against COVID-19, illustrating how inventive approaches can enhance patient care and treatment methodologies. His patents not only showcase his ingenuity but also signify a commitment to improving health outcomes through scientific research and innovation. As the landscape of medical technology continues to evolve, Patterson's contributions will undoubtedly play a pivotal role in shaping the future of therapeutic strategies.

This text is generated by artificial intelligence and may not be accurate.